Engineering T cell receptor fusion proteins using nonviral CRISPR/Cas9 genome editing for cancer immunotherapy.
Journal Information
Full Title: Bioeng Transl Med
Abbreviation: Bioeng Transl Med
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Subject Category: Engineering, Biomedical
Available in Europe PMC: Yes
Available in PMC: Yes
PDF Available: No
Related Papers from Same Journal
Transparency Score
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
"data s1."
"CONFLICT OF INTEREST STATEMENT The research described in this paper was funded by Cartherics Pty Ltd. All authors, except for SL, TK, KL and JYL are paid employees or advisors of Cartherics and hold options and/or equity in the company. SL, TK, KL and JYL are employees of ToolGen Inc."
Additional Indicators
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025